Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7268 | nTZDpa |
| Potent, selective non-thiazolidinedione PPARγ partial agonist (EC50 = 57 nM); produces ~25% maximum efficacy. Antagonizes full agonist activity by ~60% (IC50 ~ 285 nM). Displays no activity at PPARα or PPARδ receptors. Produces altered receptor conformation, and regulates adipocyte development and gene expression, in a differential manner to full PPARγ agonists. Modulates metabolism and insulin sensitivity without causing cardiac hypertrophy in mice in vivo. | |
| BCC7269 | NSC 625987 |
| Cyclin-dependent kinase (cdk) 4 inhibitor (IC50 = 0.2 μM at cdk4/cyclin D1). Displays > 500-fold selectivity over cdk2 (IC50 > 100 μM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E). | |
| BCC7270 | NTNCB hydrochloride |
| Selective, non-peptide competitive NPY Y5 antagonist. Ki values are 8.0 and 16032 nM at human recombinant Y5 and Y1 receptors respectively. Potently antagonizes NPY inhibition of forskolin-stimulated cAMP. Displays some affinity for cloned human D2 and α2C receptors (Ki values are 63 and 100 nM respectively). | |
| BCC7272 | ZK 164015 |
| Potent estrogen receptor silent antagonist. Inhibits 17β-estradiol stimulation of luciferase activity (IC50 = 0.025 μM); potently inhibits the growth of estrogen-sensitive human MCF-7 breast cancer cells in vitro (IC50 ~ 1 nM). | |
| BCC7273 | SN-6 |
| Selective Na+/Ca2+-exchange (NCX) inhibitor; displays some selectivity for NCX1. IC50 values are 2.9, 16 and 8.6 μM for inhibition of intracellular Na+-dependent 45Ca2+ uptake by cells expressing NCX1, NCX2 and NCX3 respectively. Has some affinity for mACh receptors (IC50 = 18 μM) but minimal activity against NCKX2 and various receptors and ion channels (IC50 > 30 μM). Preferentially blocks Ca2+ influx mode and is more selective for NCX isoforms than KB-R7943. Anti-ischemic; potently protects against hypoxia-induced renal tubular cell damage (IC50 = 0.63 μM). | |
| BCC7274 | CMPD-1 |
| Non-ATP-competitive, selective inhibitor of p38α-mediated MK2a (mitogen-activated protein kinase-2a) phosphorylation (apparent Ki = 330 nM). Does not inhibit p38α-mediated phosphorylation of MBP and ATF-2. Also tubulin polymerization inhibitor. Cytotoxic in glioblastoma cells at concentrations that do not affect the MK2 pathway. | |
| BCC7275 | NS 3763 |
| Selective non-competitive kainate receptor antagonist; displays selectivity for GLUK5 subunit-containing receptors (IC50 values are 1.6 and > 30 μM for homomeric GLUK5 and GLUK6 receptors respectively). Has minimal activity at AMPA and NMDA receptors (IC50> 30 μM). | |
| BCC7276 | Ro 0437626 |
| Selective P2X1 purinergic receptor antagonist (IC50 = 3 μM) that displays > 30-fold selectivity over P2X2, P2X3 and P2X2/3 receptors (IC50 > 100 μM). | |
